Subscribe
Michael Vi / Shutterstock.com
15 July 2025NewsAmericasMuireann Bolger

J&J sues over schizophrenia drug generic following patent victory

Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and Mylan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J fends off generic schizophrenia drug bids
10 July 2025   Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental health treatment | Appeals court rejects arguments that patent claims would have been obvious to a relevant artisan.
Americas
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies
10 June 2025   US appeals court confirms validity of Acadia's Nuplazid patents | Decision fends off generics from MSN Laboratories and Aurobindo Pharma until 2030s.
Americas
J&J unit could owe biotech $125m over AI-based surgical ‘night vision’ tech
3 June 2025   New York court finds Ethicon breached agreement with ChemImage over advanced imaging technologies | Parties dispute damages for IP ‘impairment’.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
J&J fends off generic schizophrenia drug bids
10 July 2025   Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental health treatment | Appeals court rejects arguments that patent claims would have been obvious to a relevant artisan.
Americas
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies
10 June 2025   US appeals court confirms validity of Acadia's Nuplazid patents | Decision fends off generics from MSN Laboratories and Aurobindo Pharma until 2030s.
Americas
J&J unit could owe biotech $125m over AI-based surgical ‘night vision’ tech
3 June 2025   New York court finds Ethicon breached agreement with ChemImage over advanced imaging technologies | Parties dispute damages for IP ‘impairment’.

More on this story

Americas
J&J fends off generic schizophrenia drug bids
10 July 2025   Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental health treatment | Appeals court rejects arguments that patent claims would have been obvious to a relevant artisan.
Americas
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies
10 June 2025   US appeals court confirms validity of Acadia's Nuplazid patents | Decision fends off generics from MSN Laboratories and Aurobindo Pharma until 2030s.
Americas
J&J unit could owe biotech $125m over AI-based surgical ‘night vision’ tech
3 June 2025   New York court finds Ethicon breached agreement with ChemImage over advanced imaging technologies | Parties dispute damages for IP ‘impairment’.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC